Latest news

Search
Categories
News archive

Introducing NLAB Saga®- a new generation silica for preparative chromatography

9 May, 2022

We are officially launching NLAB Saga® – Nanologica’s silica for preparative chromatography! NLAB Saga was developed with a clear goal in mind – to increase the availability of better and cheaper peptide and oligonucleotide-based medicines to a larger number of patients across the world, for the betterment of mankind. NLAB Saga has been specifically developed to meet the strict requirements of industrial scale purification by chromatography. Due to its exceptional mechanical and chemical stability, NLAB

Read more »

Kallelse till årsstämma i Nanologica AB (publ)

4 May, 2022

Aktieägarna i Nanologica AB (publ), org.nr 556664-5023 (”Bolaget”) kallas härmed till årsstämma torsdagen den 2 juni 2022, klockan 12.00, i The Parks lokaler på Magnus Ladulåsgatan 1, Stockholm. Rätt att delta vid stämman Aktieägare som önskar delta i årsstämman ska: dels vara registrerad i eget namn (inte förvaltarregistrerad) i den av Euroclear Sweden AB förda aktieboken tisdagen den 24 maj 2022, dels anmäla sitt deltagande så att anmälan är Bolaget tillhanda senast måndagen den 30

Read more »

Nanologica’s Interim Report Jan-Mar 2022

29 April, 2022

PERIOD IN BRIEF FINANCIAL SUMMARY Net sales for the first quarter amounted to TSEK 270 (5,622) The operating result amounted to TSEK -15,592 (-6,768) Result after tax amounted to TSEK -15,915 (-7,845) Earnings per share before and after dilution were SEK -0.57 (-0.28) Cash and cash equivalents amounted to TSEK 3,969 (57,069) as per March 31, 2022 SIGNIFICANT EVENTS IN THE FIRST QUARTER In January, a credit facility of up to MSEK 50 was signed

Read more »

Nanologicas delårsrapport jan-mar 2022

29 April, 2022

PERIODEN I KORTHET FINANSIELL SAMMANFATTNING Nettoomsättningen för första kvartalet uppgick till 270 TSEK (5 622) Rörelseresultatet uppgick till -15 592 TSEK (-6 768) Resultatet efter skatt uppgick till -15 915 TSEK (-7 845) Resultat per aktie före och efter utspädning var -0,57 SEK (-0,28) Likvida medel uppgick per den 31 mars 2022 till 3 969 TSEK (57 069) VÄSENTLIGA HÄNDELSER UNDER FÖRSTA KVARTALET I januari tecknas en lånefacilitet om upp till 50 MSEK med bolagets huvudägare

Read more »

Nanologica takes out loan of MSEK 20 within agreed credit facility

25 April, 2022

Nanologica AB (publ) has taken out a loan of MSEK 20 from the credit facility agreed in January with Flerie Invest AB. The loan is taken out to cover the company’s temporary financial needs pending expected cash flows from the operations in preparative chromatography. After this loan, MSEK 20 remains of the credit facility.   For further information, please contact: Johanna Johansson, Director IR, Communications and Marketing Ph: +46 72 211 21 90 or e-mail: ir@nanologica.com

Read more »